Dr. Robert A. Nagourney, MD
Why Do Chemotherapy Drugs Work For Some Cancer Patients and Not For Others?
Treatments should really be given more selectively, i.e. “give this chemotherapy only to those people who will benefit from it,” She said.
top of page
Nagourney Cancer Blog
Dr. Robert A. Nagourney, MD
Sep 262 min read
Metastatic Breast Cancer Claims Another Life
I received a video from an episode of Americas Got Talent, the popular TV program that features up-and-coming performers.
Dr. Robert A. Nagourney, MD
Sep 53 min read
Stage 4 Cancer Patients Need Answers Not Questions: Genomic Variants Of Uncertain Significance (VUS) Don’t Help!
Genomic findings are a first step. They find targets. The question the patient wants to answer is “Can I hit the target?”
Dr. Robert A. Nagourney, MD
Jul 183 min read
Metastatic or Recurrent Cancer Patients Can’t Afford to Guess
Cancer patients deserve better. Every patient is unique. Their treatment should be as well.
Dr. Robert A. Nagourney, MD
Jun 132 min read
For Pancreatic Cancer Patients, “the More You Explain It, The More I Don’t Understand It.” -Mark Twain
Even here in the potentially curable
pancreatic cancer patients, there is a great deal of disagreement on the best treatment.
Dr. Robert A. Nagourney, MD
Apr 292 min read
The Evolving Landscape of Pancreatic Cancer
Nagourney Cancer Institute remains committed to pioneering research and that promise real hope for those affected by pancreatic cancer.
Dr. Robert A. Nagourney, MD
Apr 23 min read
A Ray of Hope in the Fight Against Stage 4 Colon Cancer
Daniel Werner, a dedicated nurse and a loving fiancé and father, faced the grim reality of a stage 4 colon cancer diagnosis in December 2021
Dr. Robert A. Nagourney, MD
Mar 122 min read
What’s a Pancreatic Cancer Doctor to do? More Importantly: What are Their Patients to do?
Screening for Pancreatic cancer, even in the highest-risk individuals found not cost effective.
Dr. Robert A. Nagourney, MD
Mar 42 min read
Breakthrough in Pancreatic Cancer: New Blood Test for Early Detection, Could Offer Improved Therapy
Blood test results offer a “cancer signature” that distinguishes patients with pancreatic cancer from normal individuals.
Dr. Robert A. Nagourney, MD
Feb 212 min read
Much Heralded New Treatment For Pancreatic Cancer Approved by FDA: But Has it Moved The Dial?
The NAPOLI-3 trail trial median survival of 11.1 months is exactly the same as the original FOLFIRINOX regimen from 13 years ago.
Dr. Robert A. Nagourney, MD
Feb 92 min read
Functional Profiling for Cancer is Scientifically Validated by Peer-Review
One of the critical advantages of Functional Profiling over traditional genomic testing is its focus on the actual response of cancer cells.
Dr. Robert A. Nagourney, MD
Jan 313 min read
What Have Medical Oncologists Lost? Empathy!
Cancer patients approach their diagnosis with a sense of terror. One day they are fine and feeling well and the next, a terminal diagnosis.
bottom of page